A-317491是一种高亲和力、选择性的P2X3和P2X2/3受体激活拮抗剂，其对大鼠P2X3和P2X2/3的Ki值分别为22nM和92nM。
Cas No.:475205-49-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
A-317491 is a high-affinity and selective antagonist of P2X3 and P2X2/3 receptor activation, with Ki values of 22 and 92nM for rat P2X3 and P2X2/3, respectively [1]. A-317491 acts in the gp120 protein to inhibit the gp120-initiated P2X3 activation, decrease the sensitizing dorsal root ganglia (DRG) primary afferents, and reduce the signal transmission of neuropathic pain in gp120-treated rats[2]. A-317491 can be used to relieve the mechanical and thermal hyperalgesia of endometriotic rats [3].
In vitro, A-317491 (100µM) treatment of bovine chondrocytes for 24 hours reduced α,β-methyleneATP-induced NO production and decreased ATP-mediated PGE2 release in bovine chondrocytes[4].
In vivo, A-317491 treatment (30μmol/kg; s.c.; twice daily) for 10 days alleviated cancer-induced bone pain in NCTC clone 2472 cell-xenograft mouse models[5]. A single intrathecal injection of A-317491 (10μg dissolved in 20μl of normal saline) was administered over 3 days, which alleviated the overactive bladder evoked by 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis[6]. Intramuscular injections of A-317491 (60μg dissolved in normal saline) prevented the mechanical muscle hyperalgesia when administered 30 or 60min after the beginning of static contraction in rats[7].
References:
[1] Jarvis M F, Burgard E C, McGaraughty S, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat[J]. Proceedings of the national academy of sciences, 2002, 99(26): 17179-17184.
[2] Yi Z, Rao S, Ouyang S, et al. A317491 relieved HIV gp120-associated neuropathic pain involved in P2X3 receptor in dorsal root ganglia[J]. Brain Research Bulletin, 2017, 130: 81-89.
[3] Yuan M, Ding S, Meng T, et al. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain[J]. International Journal of Nanomedicine, 2017: 8171-8183.
[4] Varani K, De Mattei M, Vincenzi F, et al. Pharmacological characterization of P2X1 and P2X3 purinergic receptors in bovine chondrocytes[J]. Osteoarthritis and cartilage, 2008, 16(11): 1421-1429.
[5] Hansen R R, Nasser A, Falk S, et al. Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice[J]. European journal of pharmacology, 2012, 688(1-3): 27-34.
[6] Dong X Y, Yang Y, Luo S, et al. Upregulation of P2X3 receptors in primary afferent pathways involves in colon-to-bladder cross-sensitization in rats[J]. Frontiers in Physiology, 2022, 13: 920044.
[7] de Melo Aquino B, da Silva dos Santos D F, Jorge C O, et al. P2X3 receptors contribute to muscle pain induced by static contraction by a mechanism dependent on neutrophil migration[J]. Purinergic signalling, 2019, 15(2): 167-175.
A-317491是一种高亲和力、选择性的P2X3和P2X2/3受体激活拮抗剂，其对大鼠P2X3和P2X2/3的Ki值分别为22nM和92nM[1]。A-317491作用于gp120蛋白，抑制gp120启动的P2X3激活，减少gp120处理大鼠中背根神经节（DRG）初级传入神经的敏化，并降低神经病理性疼痛的信号传递[2]。A-317491可用于缓解子宫内膜异位症大鼠的机械性和热痛觉过敏[3]。
在体外，使用100µM的A-317491处理牛软骨细胞24小时，减少了α,β-methyleneATP诱导的一氧化氮生成，并降低了ATP介导的PGE2释放[4]。
在体内，每日两次皮下注射A-317491（30µmol/kg），持续10天，缓解了NCTC clone 2472细胞异种移植小鼠模型中癌症诱导的骨痛[5]。在3天内单次鞘内注射A-317491（10µg溶解于20µl生理盐水中），缓解了由2,4,6-三硝基苯磺酸（TNBS）诱导的结肠炎引发的膀胱过度活动[6]。在静态收缩开始后30或60分钟，肌肉注射A-317491（60µg溶解于生理盐水），可预防大鼠机械性肌肉痛觉过敏的发生[7]。
| Cell experiment [1]: | |
Cell lines | Bovine chondrocytes |
Preparation Method | Bovine chondrocytes were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin 100U/ml, streptomycin 0.1mg/ml). Seeded at a high density (1.5×106 cells/cm2) in 6-well plates, ATP (500μM) was added to the medium containing 50ng/ml recombinant IL-1β, followed by incubation with 100µM A-317491 for 24h to analyze nitric oxide and PGE2 content. |
Reaction Conditions | 100μM; 24h |
Applications | A-317491 treatment decreased ATP-mediated NO production and PGE2 release in bovine chondrocytes. |
| Animal experiment [2]: | |
Animal models | Male C3H/HeN mice |
Preparation Method | Six-week-old male C3H/HeN mice were housed in a standard environment in groups of seven with a 12h light/dark cycle and ad libitum access to water and standard diet. Bone cancer was induced in C3H/HeN mice by suspension of 1×105 NCTC 2472 clone cells in 10μl PBS. C3H/HeN mice were randomly divided into three groups according to body weight: (i) bone cancer surgery+A-317491 treatment group (30μmol/kg; dissolved in normal saline; subcutaneously injected twice daily); (ii) bone cancer surgery+vehicle control group (subcutaneous injection; twice daily). A-317491 or vehicle control was administered daily at 12:00 and 22:00. Mice were assessed for pain-related behaviors before and 10 days after surgery. |
Dosage form | 30μmol/kg; twice daily for 10 days; s.c. |
Applications | A-317491 treatment alleviated cancer-induced bone pain in NCTC clone 2472 cell-xenograft mouse models. |
References: | |
| Cas No. | 475205-49-3 | SDF | |
| 别名 | A 317491;A317491 | ||
| 化学名 | 5-[(3-phenoxyphenyl)methyl-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid | ||
| Canonical SMILES | C1CC(C2=CC=CC=C2C1)N(CC3=CC(=CC=C3)OC4=CC=CC=C4)C(=O)C5=CC(=C(C=C5C(=O)O)C(=O)O)C(=O)O | ||
| 分子式 | C33H27NO8 | 分子量 | 565.57 |
| 溶解度 | ≥ 56.6 mg/mL in DMSO, ≥ 40.73 mg/mL in EtOH with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7681 mL | 8.8406 mL | 17.6813 mL |
| 5 mM | 353.6 μL | 1.7681 mL | 3.5363 mL |
| 10 mM | 176.8 μL | 884.1 μL | 1.7681 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet